US equities
|
AAPL
$353.78
▲+6.59%
NVDA
$203.08
▼-1.75%
AMZN
$267.65
▲+6.77%
AMD
$497.90
▲+2.89%
META
$629.43
▲+1.35%
SPCX
$136.32
▼-3.53%
TSLA
$383.15
▼-3.85%
MSFT
$553.88
▲+6.31%
AAPL
$353.78
▲+6.59%
NVDA
$203.08
▼-1.75%
AMZN
$267.65
▲+6.77%
AMD
$497.90
▲+2.89%
META
$629.43
▲+1.35%
SPCX
$136.32
▼-3.53%
TSLA
$383.15
▼-3.85%
MSFT
$553.88
▲+6.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Ardelyx, Inc. - Common Stock
(NQ:
ARDX
)
3.137
+0.107 (+3.53%)
Delayed Quote
Updated: 10:24 AM EST, Nov 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Ardelyx: 3 Key Takeaways for Long-Term Investors
↗
Today 10:27 EST
Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript
↗
Today 10:00 EST
Patient awareness push and IBSRELA sales growth both gained momentum this quarter.
Via
The Motley Fool
Topics
Earnings
Economy
Intellectual Property
Kaplan Fox Deadline Alert: Ardelyx, Inc. (NASDAQ: ARDX) Investors Have Until November 16, 2026 to Seek a Lead Plaintiff Role
Today 4:50 EST
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Ardelyx (NASDAQ:ARDX) Q3 2026: Breakeven EPS, Revenue Miss, Guidance Held
↗
November 03, 2026
Via
Chartmill
ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
November 03, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
↗
November 03, 2026
Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for...
Via
MarketBeat
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
November 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
After-Hours Stock Movers: Nov. 3 Gainers and Losers
↗
November 03, 2026
Via
Chartmill
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
November 03, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
ARDX UPCOMING DEADLINE: SueWallSt Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
November 03, 2026
Time-Sensitive: Allegations focus on Ardelyx's representations that its patient-access strategy was working, while more stringent prior authorization and step edit requirements were allegedly slowing...
From
SueWallSt
Via
GlobeNewswire
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
November 03, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
November 02, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
November 02, 2026
Promise vs. Reality: Ardelyx pointed investors toward $1.75 billion in combined peak sales for IBSRELA and XPHOZAH, while the complaint alleges payer utilization-management barriers were already...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
October 31, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
October 30, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
Kaplan Fox Urges Ardelyx, Inc. (NASDAQ: ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
October 28, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
October 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
October 27, 2026
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while...
From
SueWallSt
Via
GlobeNewswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
October 27, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
ARDX Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Ardelyx, Inc. Class Action Lawsuit
October 26, 2026
San Diego, California--(Newsfile Corp. - October 26, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or...
Via
Newsfile
Topics
Lawsuit
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX
October 26, 2026
Ardelyx's chief executive, two successive chief financial officers, and its chief commercial officer are each named as individual defendants in a securities class action alleging they controlled public...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
October 23, 2026
From
Ardelyx, Inc.
Via
GlobeNewswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
October 23, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
October 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
October 20, 2026
A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were...
From
SueWallSt
Via
GlobeNewswire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
October 20, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
October 20, 2026
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
ARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
October 19, 2026
Time-Sensitive: Allegations focus on Ardelyx's representations that its patient-access strategy was working, while more stringent prior authorization and step edit requirements were allegedly slowing...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
October 16, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
Kaplan Fox Continues to Remind Ardelyx, Inc. (NASDAQ: ARDX) Investors of the Lead Plaintiff Deadline on November 16, 2026
October 16, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
